Pharmacotherapy to gene editing: potential therapeutic approaches for Hutchinson-Gilford progeria syndrome

Area of Science:

• Genetics and Molecular Biology
• Cellular and Developmental Biology
• Rare Disease Research

Background:

• Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder causing accelerated aging and premature death, primarily due to cardiovascular complications.
• The condition arises from a mutation in the LMNA gene, leading to the production of toxic progerin protein that disrupts nuclear structure and cellular function.
• Current treatments are limited, with no definitive cure available for this catastrophic disorder.

Purpose of the Study:

• To review current therapeutic strategies for managing and potentially curing Hutchinson-Gilford progeria syndrome (HGPS).
• To discuss advancements in disease models for studying HGPS.
• To explore the potential of stem cell-derived extracellular vesicles (EVs) as a novel therapeutic approach for HGPS.

Main Methods:

• Literature review of existing research on HGPS.
• Analysis of therapeutic approaches and disease models for HGPS.
• Evaluation of the potential application of extracellular vesicles in treating aging-related disorders.

Main Results:

• Several therapeutic strategies for HGPS are currently under development.
• New disease models have been created to facilitate HGPS research.
• Extracellular vesicles derived from stem cells show promise in combating aging and related conditions.

Conclusions:

• Extracellular vesicles derived from stem cells represent a promising therapeutic avenue for Hutchinson-Gilford progeria syndrome (HGPS).
• Further research into stem cell-derived EVs could lead to effective treatments for HGPS and other aging-related diseases.
• Continued development of disease models is crucial for advancing HGPS research and therapeutic discovery.